Cargando…

A noncanonical AR addiction drives enzalutamide resistance in prostate cancer

Resistance to next-generation anti-androgen enzalutamide (ENZ) constitutes a major challenge for the treatment of castration-resistant prostate cancer (CRPC). By performing genome-wide ChIP-seq profiling in ENZ-resistant CRPC cells we identify a set of androgen receptor (AR) binding sites with incre...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Yundong, Wei, Ting, Ye, Zhenqing, Orme, Jacob J., Lin, Dong, Sheng, Haoyue, Fazli, Ladan, Jeffrey Karnes, R., Jimenez, Rafael, Wang, Liguo, Wang, Liewei, Gleave, Martin E., Wang, Yuzhuo, Shi, Lei, Huang, Haojie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943793/ https://www.ncbi.nlm.nih.gov/pubmed/33750801 http://dx.doi.org/10.1038/s41467-021-21860-7

Ejemplares similares

Androgen receptor (AR) antagonism triggers acute succinate‐mediated adaptive responses to reactivate AR signaling
por: Saxena, Neetu, et al.
Publicado: (2021)

Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer
por: Zhao, Jingwen, et al.
Publicado: (2016)

GATA2 as a potential metastasis-driving gene in prostate cancer
por: Chiang, Yan Ting, et al.
Publicado: (2014)

Regulation of AR mRNA translation in response to acute AR pathway inhibition
por: Somasekharan, Syam Prakash, et al.
Publicado: (2021)

Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer
por: He, Yundong, et al.
Publicado: (2018)

Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC
por: White, Ralph E., et al.
Publicado: (2023)

Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide
por: Gurioli, Giorgia, et al.
Publicado: (2020)

Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
por: Li, Qiuhui, et al.
Publicado: (2018)

Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer
por: Shiota, Masaki, et al.
Publicado: (2015)

SPOP mutation induces replication over-firing by impairing Geminin ubiquitination and triggers replication catastrophe upon ATR inhibition
por: Ma, Jian, et al.
Publicado: (2021)

Reformation of the chondroitin sulfate glycocalyx enables progression of AR-independent prostate cancer
por: Al-Nakouzi, Nader, et al.
Publicado: (2022)

The Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer
por: Zheng, Zeyuan, et al.
Publicado: (2022)

LncRNA PCBP1-AS1-mediated AR/AR-V7 deubiquitination enhances prostate cancer enzalutamide resistance
por: Zhang, Boya, et al.
Publicado: (2021)

RETRACTED ARTICLE: Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC
por: Zhang, Boya, et al.
Publicado: (2021)

Retraction Note: Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC
por: Zhang, Boya, et al.
Publicado: (2023)

BIRC6 Protein, an Inhibitor of Apoptosis: Role in Survival of Human Prostate Cancer Cells
por: Low, Christopher G., et al.
Publicado: (2013)

Dual inhibition of AKT‐mTOR and AR signaling by targeting HDAC3 in PTEN‐ or SPOP‐mutated prostate cancer
por: Yan, Yuqian, et al.
Publicado: (2018)

Immune evasion strategies of neuroendocrine-like Enzalutamide resistant prostate cancer
por: Bishop, Jennifer L, et al.
Publicado: (2013)

Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer
por: Thaper, Daksh, et al.
Publicado: (2018)

Triptolide Inhibits the AR Signaling Pathway to Suppress the Proliferation of Enzalutamide Resistant Prostate Cancer Cells
por: Han, Yangyang, et al.
Publicado: (2017)

The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis
por: Iris Luk, Sze Ue, et al.
Publicado: (2014)

Mutational Landscapes of Sequential Prostate Metastases and Matched Patient Derived Xenografts during Enzalutamide Therapy
por: Kohli, Manish, et al.
Publicado: (2015)

Noncanonical HPV carcinogenesis drives radiosensitization of head and neck tumors
por: Schrank, Travis P., et al.
Publicado: (2023)

Non-drug efflux function of ABCC5 promotes enzalutamide resistance in castration-resistant prostate cancer via upregulation of P65/AR-V7
por: Chen, Haojie, et al.
Publicado: (2022)

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer
por: Salvi, Samanta, et al.
Publicado: (2016)

Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation
por: Simon, Iris, et al.
Publicado: (2021)

Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation
por: Chen, Sisi, et al.
Publicado: (2022)

Selection, Addiction and Catalysis: Emerging Trends for the Incorporation of Noncanonical Amino Acids into Peptides and Proteins in Vivo
por: Mayer, Clemens
Publicado: (2019)

A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design
por: Freedland, Stephen J, et al.
Publicado: (2021)

HC-1119, a deuterated Enzalutamide, inhibits Migration, Invasion and Metastasis of the AR-positive triple-negative breast Cancer cells
por: Wu, Xuehong, et al.
Publicado: (2022)

Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor
por: Coleman, Daniel J., et al.
Publicado: (2016)

LOX-1 Activation by oxLDL Induces AR and AR-V7 Expression via NF-κB and STAT3 Signaling Pathways Reducing Enzalutamide Cytotoxic Effects
por: Duprat, Felix, et al.
Publicado: (2023)

Novel non-AR therapeutic targets in castrate resistant prostate cancer
por: Toren, Paul J., et al.
Publicado: (2013)

Noncanonical activation of GLI signaling in SOX2(+) cells drives medulloblastoma relapse
por: Swiderska-Syn, Marzena, et al.
Publicado: (2022)

Cell-cycle coupled expansion of AR activity promotes cancer progression
por: McNair, Christopher, et al.
Publicado: (2016)

LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer
por: Wang, Dejie, et al.
Publicado: (2015)

Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer
por: Erb, Holger H. H., et al.
Publicado: (2020)

Loss of Nuclear Functions of HOXA10 Is Associated With Testicular Cancer Proliferation
por: Chen, Ruiqi, et al.
Publicado: (2018)

Development of an addiction recovery patient-reported outcome measure: Response to Addiction Recovery (R2AR)
por: Okrant, Elisabeth, et al.
Publicado: (2023)

Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer
por: Kafka, Mona, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_remc1v7a83lavi6jonkd0ikr24